IOL implantation improves sleep quality

Article

Removal of a cataract and implantation of an intraocular lens (IOL) improves overall sleep quality and sleep latency, according to a study published online before print.

Removal of a cataract and implantation of an intraocular lens (IOL) improves overall sleep quality and sleep latency, according to a study published online before print in Investigative Ophthalmology and Visual Science.

Researchers in the UK were seeking information on how the melanopsin-based photosensitive retinal ganglion cells (pRGC's) regulate sleep/wake timing in patients who have cataracts. They used the Pittsburgh Sleep Quality Index (PSQI) to assess quality of sleep in 961 patients undergoing cataract surgery. The patients received either an ultraviolet blocking (UVB) clear IOL (498 patients) or a blue-filtering (BF) IOL (463 patients). The patients completed the PSQI questionnaires 1 month preoperatively and 1, 6 (UVB-IOL patients only) and 12 months postoperatively.

The researchers found that cataract removal - regardless of the type of IOL implanted - improved overall sleep quality significantly 1 month postoperatively. Sleep latency (the shortening in time to fall asleep) also improved, and the improvement was sustained at 6 and 12 months postoperatively.

"The key finding of this study is the sustained improvement in sleep latency after surgery irrespective of IOL type implanted. This result highlights a significant benefit of cataract surgery in addition to improvement in visual acuity," the researchers wrote.

To read the full study, visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.